BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY

NCT ID: NCT02645799

Last Updated: 2018-01-11

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 270 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-04-30
• Study Completion Date: 2018-11-30

Brief Summary

The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM).

Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM.

Detailed Description

This is a phase IIb, prospective, multi-center, multi-national, randomized, double-blind, two-arm, 1:1 (escalating dose LABR-312 vs. placebo) clinical trial.

In both study arms, all target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Lesions that are planned to be treated must be declared and recorded at the time of randomization.

Randomization will be stratified by the presence or absence of insulin treatment, HbA1c level (<7.5% vs. ≥7.5%), and by pre-procedure monocyte count (≥500/uL or below).

Subjects (n=~270) will be randomized to receive either the study drug LABR-312 or the placebo. Conditionally to ongoing safety monitoring, dose escalation of LABR-312 in the study arm will be performed: 0.01 mg (first 45 patients vs. 45 patients receiving placebo), up to 0.03 mg (next consecutive 45 patients vs. 45 patients receiving placebo) and up to 0.08 mg (final 45 consecutive patients vs. 45 patients receiving placebo). If a decision is made not to dose escalate, recruitment will continue with the highest dose level deemed safe by the ongoing safety monitoring, until approximately 270 subjects are randomized.

In the LABR-312 group, 3 doses will therefore be tested, resulting in 6 possibilities:

Group 1: Low dose 0.01 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

Group 2: Intermediate dose Up to 0.03 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

Group 3: High dose Up to 0.08 mg LABR-312 or equivalent volume of placebo (saline) administered IV.

The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1year post randomization.

OCT follow-up will be performed at 9 months.

Conditions

Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

LABR-312

LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Three (3) doses will be tested:

Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.

OCT follow-up will be performed at 9 months.

Group Type: ACTIVE_COMPARATOR

LABR-312

Intervention Type: DRUG

administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

saline

Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.

Three (3) doses will be tested:

Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.

OCT follow-up will be performed at 9 months.

Group Type: PLACEBO_COMPARATOR

Saline (placebo)

Intervention Type: DRUG

administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

Interventions

LABR-312

administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

Intervention Type: DRUG

Saline (placebo)

administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patient has medically treated diabetes mellitus (is on insulin or oral or injectable hypoglycemic medications).

2. Patient is eligible and has an indication for PCI with a drug eluting stent (patient may be consented prior to diagnostic angiography with possible PCI).

3. Patient presents with angina (stable or unstable), silent ischemia (in absence of symptoms must have a positive stress test, FFR ≤0.80, or angiographic stenosis of ≥70%), NSTEMI, or recent STEMI (>7 days from procedure).

4. Non-target vessel PCI are allowed prior to randomization depending on the time interval and conditions as follows:

• During Baseline Procedure:
• PCI of non-target vessels performed during the baseline procedure itself immediately prior to randomization, if successful and uncomplicated, defined as: <50% visually estimated residual diameter stenosis, TIMI Grade 3 flow, no dissection ≥ NHLBI type C, no perforation, no persistent ST segment changes, no prolonged chest pain, no TIMI major or BARC type 3 bleeding.

• Less than 24 hours prior to Baseline Procedure:

1. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥2.25mm to ≤4.2mm and diameter stenosis ≥50% to <100%.

2. Thrombolysis in Myocardial Infarction (TIMI) flow 2 or 3. If more than 1 target lesion will be treated, the reference vessel diameter and lesion length of each must meet the above criteria.

Exclusion Criteria

• 24 hours-30 days prior to Baseline Procedure:
• PCI of non-target vessels 24 hours to 30 days prior to randomization if successful and uncomplicated as defined above.
• In cases where non-target lesion PCI has occurred 24-72 hours prior to the baseline procedure, at least 2 sets of cardiac biomarkers must be drawn at least 6 and 12 hours after the non-target vessel PCI.
• If cardiac biomarkers are initially elevated above the local laboratory upper limit of normal, serial measurements must demonstrate that the biomarkers are falling.

• Over 30 days prior to Baseline Procedure:
• PCI of non-target vessels performed greater than 30 days prior to procedure whether or not successful and uncomplicated.

5. All non-target lesions (i.e. those not meeting angiographic criteria for the study) should be treated prior to randomization. All target lesions must be planned to be treated during the index procedure. The investigator will declare which target lesions are intended for treatment at the time of randomization. In the event that all target lesions cannot be treated (e.g. due to contrast load), staged procedure should be delayed preferably at least 2 weeks after the index PCI, and those lesions will be considered non-target lesions. Any such planned staged lesions must be declared at the end of the index procedure.

6. Prior target-vessel PCI is allowed if it occurred ≥6 months prior to randomization and no restenosis is present, or if re-intervention is planned on the restenotic lesion(s) as a non-target lesion.

7. The patient or legal guardian is willing and able to provide written informed consent and comply with follow-up visits and the testing schedule.

1. STEMI within 7 days of presentation to the first treating hospital, whether a transfer facility or the study hospital

2. PCI within the 24 hours prior to randomization

3. Cardiogenic shock (defined as persistent hypotension [systolic blood pressure <90 mm Hg] or requiring pressors or hemodynamic support, including IABP)

4. Known left ventricular ejection fraction <30%

5. Relative or absolute contraindication to DAPT for 6 months (including planned surgeries that cannot be delayed or chronic oral anticoagulant requirement, such as atrial fibrillation or prosthetic heart valve)

6. Hemoglobin <10 g/dL

7. Platelet count <100,000 cells/mm3 or >700,000 cells/mm3

8. White blood cell count <3,000 cells/mm3

9. Major and clinically significant active infection

10. Clinically significant liver disease

11. Renal insufficiency as defined by an estimated Glomerular Filtration Rate, GFR <40 ml/min by the MDRD formula

12. Active peptic ulcer or active bleeding from any site

13. Bleeding from any site requiring active medical attention within the prior 8 weeks

14. History of bleeding diathesis or coagulopathy or likely to refuse blood transfusions

15. Cerebrovascular accident (CVA) or has any permanent neurological defect as a result of CVA

16. Known allergy to the study stent components or protocol-required concomitant medications: alendronate, liposomal medications, aspirin, clopidogrel and prasugrel and ticagrelor, heparin and bivalirudin, or iodinated contrast that cannot be adequately pre-medicated

17. Subject is taking Bisphosphonates, including Alendronate (Fosamax); Clodronate (Bonefos); Etidronate (Didronel / Didrocal); Ibandronate (Bondronat); Pamidronate (Aredia); Risedronate (Actonel); Tiludronate (Skelid); Zoledronic acid (Zometa), or any other bisphosphonates not listed above.

18. Any co-morbid condition that may cause non-compliance with the protocol (e.g. dementia, substance abuse, etc.) or reduce life expectancy to <24 months (e.g. cancer, heart failure, lung disease)

19. Patient is participating in or plans to participate in any other investigational drug or device trial that has not reached its primary endpoint.

20. Women who are pregnant or breastfeeding (women of child-bearing potential must have a negative pregnancy test within one week before index procedure).

21. Women who intend to become pregnant within 12 months after the index procedure

22. Patient has received an organ transplant or is on a waiting list for an organ transplant.

23. Patient is receiving or scheduled to receive chemotherapy within 30 days before or any time after the index procedure.

24. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease. Inhaled steroid and steroid use for contrast-allergy prophylaxis or treatment are allowed.

1. Unprotected left main lesions >30% or left main intervention.

2. Primary PCI for STEMIOstial RCA lesion within 5 mm of ostium*

3. Coronary artery disease judged more suitable for surgical revascularization per guidelines and local heart team discussion.

4. Another lesion in either the target vessel or non-target vessel is present that requires or has a high probability of requiring PCI within 9 months after the index procedure.

5. Bifurcation lesions with planned or high probability of dual stent implantation*

6. Target lesions located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft

7. Heavily tortuous or angulated lesions*

8. Lesions containing large thrombus*

9. Total occlusions*

10. Lesions present within 10mm of another lesion treated by PCI*

11. Restenotic lesions* *Refers to target lesions. Non-target lesions not meeting these criteria may be treated as appropriate.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BIOrest Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philippe Généreux, MD

Role: PRINCIPAL_INVESTIGATOR

Cardiovascular Research Foundation (CRF)

Locations

Kaplan Medical Center

Rehovot, , Israel

Countries

Israel

References

Genereux P, Chernin G, Assali AR, Peruga JZ, Robinson SD, Schampaert E, Bagur R, Mansour S, Rodes-Cabau J, McEntegart M, Gerber R, L'Allier P, de Silva R, Daneault B, Aggarwal SK, Dzavik V, Ozan MO, Ben-Yehuda O, Maehara A, Stone GW, Jonas M. Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial. Am Heart J. 2022 Jul;249:45-56. doi: 10.1016/j.ahj.2022.03.004. Epub 2022 Mar 17.

Reference Type: DERIVED

PMID: 35305955 (View on PubMed)

Other Identifiers

LA-II-02

Identifier Type: -

Identifier Source: org_study_id